17th Meet The Professor Advanced International Breast Cancer Course - (AIBCC) - Collegio degli Oncologi Medici Universitari
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Sezione di Oncologia [ Meet the Professor ] 17th Meet The Professor Advanced International Breast Cancer Course (AIBCC) September 30 – October 1, 2021
Sezione di Oncologia
[Preliminary Program]
Thursday, September 30th
Webinar Live
14.30 Registration of participants
14.45 Introduction to the Conference
Pier Franco Conte, Gabriel N. Hortobagyi, Valentina Guarneri, Philip Poortmans
SESSION I
Chairpersons: Hesham Ahmed Gaballah Elghazaly, Pierfranco Conte
15.00 Obesity and Cancer
Roberto Vettor
15.20 Management of women BRCA1/2 and other predisposition gene mutations
Shani Paluch-Shimon
15.40 Axillary dissection: still an option?
Elefterios Mamounas
16.00 Hot topics in breast cancer RT
Philip Poortmans
16.20 Clinical impact of genomics in BC
Aleix Prat
16.40 PIK3CA testing: from technical aspects to clinical application
Sybille Loibl
17.00 Prognostic signatures to guide treatment decision
Gabriel N. Hortobagyi
17.20 Q&A
17.30 Adjourn
Friday, October 1st
Onsite session - Sessione residenziale
The onsite session will be held Centro Congressi Villa Ottoboni Via Padre E. Ramin, 1 Padova
This session will be in Italian language and will be addressed to Italian participants
SESSIONE II –PRESENTAZIONE E DISCUSSIONE DI CASI CLINICI
Moderatori: Pier Franco Conte, Valentina Guarneri
10.00 Caso clinico 1: omissione di RT in pazienti anziani con tumore a basso rischio
10.20 Caso clinico 2: cT1c, cN0 HER2+tumore: neo vs adiuvante (opzione per intensificare o ridurre la
terapia) - Cristina FalciSezione di Oncologia
10.40 Caso clinico 3: terapia post-neoadiuvante in pazienti con RD (sottolineando il concetto di RCB e la
caratterizzazione di RD) - Federica Miglietta
11.00 Caso clinico 4: malattia oligometastatica – Grazia Vernaci
11.20 Caso clinico 5: metastasi cerebrali – Gaia Griguolo
11.40 Caso clinico 6: quando interrompere la terapia attiva – Tommaso Giarratano
12.00 Chiusura dei lavori
Webinar Live
SESSION III
Chairpersons: Jacek Jassem, Valentina Guarneri
15.00 Adjuvant CDK4/6i for HR+ disease: reconciling data from randomized trials
Valentina Guarneri
15.20 Immunotherapy for early TNBC: hopes and hypes
Hope Rugo
15.40 Early BRCAm tumors: PARPi are coming!
Andrew Tutt
16.00 Neoadjuvant therapy for early breast cancer: beyond the pCR dogma
Pier Franco Conte
16.20 Q&A
16.40 Antibody Drug Conjugates for BC
Frederik Marmè
17.00 Targeting unconventional pathways in Luminal BC
Maria Vittoria Dieci
17:20 Treatment algorithm for HR+/HER2- ABC
Stephen Johnston
17.40 Treatment algorithm for HER2+ ABC
Sandra Swain
18.00 Treatment algorithm and new options for TN ABC
Miguel Martin
18.20 Q&A
18.30 AdjournSezione di Oncologia
Async Distance Learning - October 15th, 2021 – October 14th, 2022
[Program]
Lectures will be launched on the virtual platform on October 15th
All the lectures will takes 20’
SESSION I
1. Obesity and Cancer
Roberto Vettor
2. Management of women BRCA1/2 and other predisposition gene mutations
Shani Paluch-Shimon
3. Axillary dissection: still an option?
Elefterios Mamounas
4. 16.00 Hot topics in breast cancer RT
Philip Poortmans
5. Clinical impact of genomics in BC
Aleix Prat
6. PIK3CA testing: from technical aspects to clinical application
Sybille Loibl
7. Prognostic signatures to guide treatment decision
Gabriel N. Hortobagyi
SESSION II
1. Adjuvant CDK4/6i for HR+ disease: reconciling data from randomized trials
Valentina Guarneri
2. Immunotherapy for early TNBC: hopes and hypes
Hope Rugo
3. Early BRCAm tumors: PARPi are coming!
Andrew Tutt
4. Neoadjuvant therapy for early breast cancer: beyond the pCR dogma
Pier Franco Conte
5. Antibody Drug Conjugates for BC
Frederik Marmè
6. Targeting unconventional pathways in Luminal BC
Maria Vittoria Dieci
7. Treatment algorithm for HR+/HER2- ABCSezione di Oncologia
Stephen Johnston
8. Treatment algorithm for HER2+ ABC
Sandra Swain
9. Treatment algorithm and new options for TN ABC
Miguel Martin
[Aims and structure]
Mortality from breast cancer is declining in most countries thanks to effective screening programs, early
diagnosis, molecular characterization of the different subtypes and biology-driven treatments. A
multidisciplinary management of breast cancer patients is therefore the key to success and a breast
multidisciplinary team should include - besides the “classic” clinical specialties - pathologists, molecular
biologists and geneticists. Furthermore, the availability of multiple diagnostic and therapeutic choices, the
increasing costs of new technologies and drugs and the issue of sustainability represent a new challenge for
socially-responsible clinicians. With this goal in mind, the Programme includes lectures on molecular
characterization, updated treatments of early and advanced disease, management of difficult cases and
hereditary syndromes and issues of sustainability and drug access across countries.
The 17th edition of AIBCC is divided in a sync and an async part.
The sync part will be organized into:
Two live sessions in english, scheduled on September 30th and October 1st 2021, with the participation of
speakers connected by various countries and addressed to Italian and foreign participants.
One residential session in presence (if health conditions allow it) with the presentation and discussion of
clinical cases from Italian speakers. This session is addressed to Italian participants, a part of which will
follow the live event online remotely while a small number of participants, from the Veneto Region, will be
present in the Congress venue.
The async part will consist of a one-year FAD (distance learning) from October 15 2021 to October 14 2022
that will contain all the lessons of the two webinars. It will be free and also accessible to those who have not
participated at the sync course.
The Conference is addressed to medical oncologists, pathologists, breast surgeons, radiation oncologists and
basic scientists who will have the opportunity to interact with breast cancer leaders and exchange
experiences in a friendly atmosphere.
[Addressed to]
Gynaecologists and obstetrics, medical oncologists, pathologists, radiologists, radiation oncologists,
surgeons. Biologists, pharmacists, and nurses.
[Directors]
Pierfranco Conte
Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padova (I)Sezione di Oncologia Valentina Guarneri Division of Medical Oncology 2 Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padova (I) Gabriel N. Hortobagyi Department of Breast Medical Oncology The University of Texas - MD Anderson Cancer Center Houston (USA) Philip Poortmans Former president of ESTRO and of ECCO Department of Radiation Oncology Iridium Netwerk University of Antwerp Wilrijk-Antwerp (B) [Scientific Committee] Hesham Ahmed Gaballah Elghazaly Department of Clinical Oncology and nuclear medicine University of Ainshams Cairo (EG) Jacek Jassem Department of Oncology and Radiotherapy Medical University of Gdansk (PL) Stephen Johnston NIHR Biomedical Research Centre for Cancer Royal Marsden NHS Foundation Trust & Institute of Cancer Research London (UK) Sibylle Loibl German Breast Group University of Frankfurt (D) Eleuterios Mamounas Comprehensive Breast Program MD Anderson Cancer Center Orlando Orlando (F) Miguel Martin Medical Oncology Service Hospital Universitario Gregorio Marañon Madrid (E) Stefania Migliuolo Europa Donna Italia Milano (I)
Sezione di Oncologia Fedro Alessandro Peccatori Department of Medical Oncology European Institute of Oncology (IEO) Milano (I) Aleix Prat Medical Oncology Department Hospital Clinic Barcellona (E) Sandra Swain M. Research Development Georgetown University Medical Center Washington (USA) [Speakers] Pierfranco Conte Division of Medical Oncology 2 Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padova (I) Maria Vittoria Dieci Division of Medical Oncology 2 Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padova (I) Cristina Falci Division of Medical Oncology 2 Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padua (I) Tommaso Giarratano Division of Medical Oncology 2 Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padua (I) Gaia Griguolo Division of Medical Oncology 2 Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padua (I) Gabriel N. Hortobagyi Department of Breast Medical Oncology The University of Texas - MD Anderson Cancer Center Houston (USA)
Sezione di Oncologia Jacek Jassem Department of Oncology and Radiotherapy Medical University of Gdansk (PL) Stephen Johnston NIHR Biomedical Research Centre for Cancer Royal Marsden NHS Foundation Trust & Institute of Cancer Research London (UK) Sibylle Loibl German Breast Group University of Frankfurt (D) Eleuterios Mamounas Comprehensive Breast Program MD Anderson Cancer Center Orlando Orlando (F) Frederik Marmè National Center for Tumor Diseases (NCT) University of Heidelberg (DE) Miguel Martin Medical Oncology Service Hospital Universitario Gregorio Marañon Madrid (E) Federica Miglietta Division of Medical Oncology 2 Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padua (I) Shani Paluch-Shimon Sharett Institute of Oncology Hadassah University Hospital Jerusalem (IL) Philip Poortmans Former president of ESTRO and of ECCO Department of Radiation Oncology Iridium Netwerk University of Antwerp Wilrijk-Antwerp (B) Aleix Prat Medical Oncology Department Hospital Clinic Barcellona (E) Hope Rugo UCSF Carol Franc Buck Breast Care Center Breast Oncology Clinical Trials Program San Francisco (USA)
Sezione di Oncologia Sandra Swain M. Research Development Georgetown University Medical Center Washington (USA) Andrew Tutt Breakthrough Breast Cancer Research Unit Kings College Londra (UK) Grazia Vernaci Division of Medical Oncology 2 Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padua (I) Roberto Vettor Division of Internal Medicine University of Padova (I)
You can also read
